Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma – PHARMA
PumaBiotech (@pumabiotech) / Twitter
Puma – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma – PHARMA
Medical Affairs eLearning - MSL Society
Buy Hering Pharma Muira Puma Mother Tincture Q 30ml | ShopHealthy.in
PharmaBg
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma – PHARMA
Puma Men – PHARMA
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Puma Biotechnology
Puma Biotechnology
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
